TrialJapanese journal of clinical oncology2023

Adjuvant nivolumab versus placebo following radical surgery for high-risk muscle-invasive urothelial carcinoma: a subgroup analysis of Japanese patients enrolled in the phase 3 CheckMate 274 trial.

Yoshihiko Tomita et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.